<HTML xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en" dir="ltr">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki  ltr ns-0 ns-subject page-Team_TU-Eindhoven_KillingMechanism"><DIV id="globalWrapper"><DIV id="top-section"><DIV id="p-logo"><A href="/Main_Page" title="Main Page">&quot;
	    </A></DIV><DIV id="menubar" class="left-menu noprint"><UL><LI class="selected"><A href="/Team:TU-Eindhoven/KillingMechanism">Page               </A></LI><LI class="new"><A href="/wiki/index.php?title=Talk:Team:TU-Eindhoven/KillingMechanism&amp;action=edit&amp;redlink=1">Discussion               </A></LI><LI><A href="/wiki/index.php?title=Team:TU-Eindhoven/KillingMechanism&amp;action=edit">View source               </A></LI><LI><A href="/wiki/index.php?title=Team:TU-Eindhoven/KillingMechanism&amp;action=history">History               </A></LI><LI style="color:white;cursor:default">teams</LI></UL></DIV><DIV class="right-menu noprint" id="menubar"><UL><LI id="pt-login"><A href="/wiki/index.php?title=Special:UserLogin&amp;returnto=Team:TU-Eindhoven/KillingMechanism" title="You are encouraged to log in; however, it is not mandatory [o]" accesskey="o">Log in</A></LI></UL></DIV><DIV id="search-controls" class="noprint"><FORM action="/Special:Search" id="searchform"> </FORM></DIV></DIV><DIV id="content"><H1 class="firstHeading">Team:TU-Eindhoven/KillingMechanism</H1><DIV id="bodyContent"><H3 id="siteSub" class="noprint">From 2013.igem.org</H3><DIV class="navwrapper"><DIV class="container"><DIV class="navbar"><DIV class="navbar-inner"><UL class="nav"><LI id="tue-menu-home"><A href="/Team:TU-Eindhoven">Home</A></LI><LI id="tue-menu-team"><A href="/Team:TU-Eindhoven/Team">Team</A></LI><LI id="tue-menu-project" class="dropdown"><A class="dropdown-toggle" data-toggle="dropdown" href="#">Project </A></LI><LI><A href="/Team:TU-Eindhoven/Project">Abstract</A></LI><LI><A href="/Team:TU-Eindhoven/Description">Project Description</A></LI><LI><A href="/Team:TU-Eindhoven/Background">Background</A></LI><LI><A href="/Team:TU-Eindhoven/Chasis">The Chassis</A></LI><LI><A href="/Team:TU-Eindhoven/Production">Potential Contrast Agents</A></LI><LI><A href="/Team:TU-Eindhoven/KillingMechanism">Kill Switch</A></LI><LI><A href="/Team:TU-Eindhoven/Applications">Applications</A></LI><LI class="nav-header">Results</LI><LI><A href="/Team:TU-Eindhoven/Results">Main Results</A></LI><LI><A href="/Team:TU-Eindhoven/Parts">Parts Submitted</A></LI><LI class="nav-header">Outlook</LI><LI><A href="/Team:TU-Eindhoven/FutureProspects">Future Steps</A></LI><LI class="nav-header">Others</LI><LI><A href="/Team:TU-Eindhoven/Attributions">Attributions</A></LI><LI><A href="/Team:TU-Eindhoven/Collaboration">Collaboration</A></LI><LI><A href="/Team:TU-Eindhoven/Achievements">Achievements</A></LI></UL><LI id="tue-menu-wetlab" class="dropdown"><A class="dropdown-toggle" data-toggle="dropdown" href="#">Wetlab </A></LI><LI><A href="/Team:TU-Eindhoven/Wetlab">Overview</A></LI><LI><A href="/Team:TU-Eindhoven/Preparation">Preparation</A></LI><LI class="nav-header">Lab Reports</LI><LI><A href="/Team:TU-Eindhoven/MRIProcessing">MRI Data Processing</A></LI><LI><A href="/Team:TU-Eindhoven/AnearobicTesting">Anaerobic FNR Testing</A></LI><LI><A href="/Team:TU-Eindhoven/CESTAgentTesting">CEST Agent Testing</A></LI><LI><A href="/Team:TU-Eindhoven/LabJournal">Lab Journal</A></LI><LI id="tue-menu-drylab" class="dropdown"><A class="dropdown-toggle" data-toggle="dropdown" href="#">Drylab </A></LI><LI><A href="/Team:TU-Eindhoven/Modeling">Summary</A></LI><LI><A href="/Team:TU-Eindhoven/ProteinSelection">Protein Selection</A></LI><LI class="nav-header">Contrast Mechanism</LI><LI><A href="/Team:TU-Eindhoven/StochasticModel">Decoy Sites</A></LI><LI><A href="/Team:TU-Eindhoven/ODEModel">FNR Dynamics</A></LI><LI><A href="/Team:TU-Eindhoven/FNRPromotor">FNR Promotor</A></LI><LI><A href="/Team:TU-Eindhoven/IntegralModel">Integral Model</A></LI><LI class="nav-header">Bacteria in the Body</LI><LI><A href="/Team:TU-Eindhoven/PBPK">Ganciclovir Distribution</A></LI><LI><A href="/Team:TU-Eindhoven/TimeKill">Time-kill Behavior</A></LI><LI id="tue-menu-safety" class="dropdown"><A class="dropdown-toggle" data-toggle="dropdown" href="#">Safety </A></LI><LI><A href="/Team:TU-Eindhoven/Safety">Overview</A></LI><LI><A href="/Team:TU-Eindhoven/LabSafety">Lab Safety</A></LI><LI><A href="/Team:TU-Eindhoven/PublicSafety">Public and Environmental Safety</A></LI><LI><A href="/Team:TU-Eindhoven/SafetyiGEM">Biosafety Within iGEM</A></LI><LI id="tue-menu-society" class="dropdown"><A class="dropdown-toggle" data-toggle="dropdown" href="#">Society </A></LI><LI><A href="/Team:TU-Eindhoven/Outreach">Outreach</A></LI><LI><A href="/Team:TU-Eindhoven/Society">Human Practice</A></LI><LI id="tue-menu-notebook"><A href="/Team:TU-Eindhoven/Notebook">Notebook</A></LI></DIV></DIV></DIV></DIV><DIV class="tue-content container"><TABLE id="toc" class="toc"><TBODY><TR><TD><DIV id="toctitle"><H2>Contents</H2></DIV><UL><LI class="toclevel-1 tocsection-1"><A href="#The_Kill_Switch_as_a_Safety_Lock"><SPAN class="tocnumber">1</SPAN><SPAN class="toctext">The Kill Switch as a Safety Lock</SPAN></A></LI><LI class="toclevel-2 tocsection-2"><A href="#The_Kill_Switch_in_Detail:_The_Ganciclovir_.2FThymidine_Kinase_System"><SPAN class="tocnumber">1.1</SPAN><SPAN class="toctext">The Kill Switch in Detail: The Ganciclovir /Thymidine Kinase System</SPAN></A></LI><LI class="toclevel-2 tocsection-3"><A href="#The_TK.2FGCV_System:_Implementation"><SPAN class="tocnumber">1.2</SPAN><SPAN class="toctext">The TK/GCV System: Implementation</SPAN></A></LI><LI class="toclevel-2 tocsection-4"><A href="#The_Alternative_System:_The_5-Fluorocytosine.2F_Cytosine_Deaminase_System"><SPAN class="tocnumber">1.3</SPAN><SPAN class="toctext">The Alternative System: The 5-Fluorocytosine/ Cytosine Deaminase System</SPAN></A></LI><LI class="toclevel-2 tocsection-5"><A href="#References"><SPAN class="tocnumber">1.4</SPAN><SPAN class="toctext">References</SPAN></A></LI></UL></TD></TR></TBODY></TABLE><H1><SPAN class="mw-headline" id="The_Kill_Switch_as_a_Safety_Lock">The Kill Switch as a Safety Lock</SPAN></H1><DIV class="tue-abstract">
In order to terminate our device after the CEST MRI has been acquired, we propose the implementation of the HSV-TK/GCV system in our bacteria. The implementation of this system requires that the CEST contrast producing bacteria are transformed with HSV Thymidine Kinase, so that cell death can be induced when the prodrug Ganciclovir is injected into the system. Directed cell death will only be induced in the cells that express the TK enzyme. This means that by implementing this controllable safety lock we can terminate our bacterial device at any point of the MRI process by administering Ganciclovir to the patient.
<P>
We propose to use this system as our killing mechanism, considering that it is well characterized and used in applications related to the principle of our device. However, we also suggest an alternative killing mechanism that could be implemented if the first one was to fail in successfully deactivating and eliminating our device from the patient.
</P></DIV><H2><SPAN class="mw-headline" id="The_Kill_Switch_in_Detail:_The_Ganciclovir_.2FThymidine_Kinase_System">The Kill Switch in Detail: The Ganciclovir /Thymidine Kinase System</SPAN></H2><DIV class="tue-float tue-float-right span8"><DIV class="tue-caption"><SPAN class="tue-caption-figure"><SPAN class="tue-refid">kmIFigure</SPAN></SPAN> <SPAN class="tue-caption-text">Cell death induced by the Ganciclovir /Thymidine Kinase system in the CEST protein producing bacteria.</SPAN></DIV></DIV><P>A rapidly evolving research area in the field of oncology is the one focused on bacterial based cancer therapies. In this type of therapies, bacteria like <I>E. Coli</I> and <I>Salmonella typhimurium</I> are used as tumor targeting systems. These bacteria are used to deliver cytotoxic agents, immunostimulatory cytokine, and genetic material to enable host-cell production of these molecules, and induce cell death in this way. <SPAN class="tue-reference"><SPAN class="tue-refid">forbesBact</SPAN>N.S. Forbes, Engineering the perfect(bacterial) cancer therapy. <I>Nature</I> , 785-794 (2010)</SPAN> Using the bacteria for delivering genetic material to the tumor cells is similar to the suicide gene therapy, also known as <A class="tue-tooltip" data-toggle="tooltip" data-placement="top" title="" data-original-title="gene-directed enzyme prodrug therapy">GDEPT</A>, which is widely used in cancer treatment. <SPAN class="tue-reference"><SPAN class="tue-refid">BugajNextGenTher</SPAN>L.J. Bugaj, D.V. Schaffer, Bringing next-generation therapeutics to the clinic through synthetic biology. <I>Current Opinion in Chemical Biology</I><B>16</B>, 355-361 (2012)</SPAN> One of the best characterized and used GDEPT systems is the <A class="tue-tooltip" data-toggle="tooltip" data-placement="top" title="" data-original-title="herpes simplex virus Thymidine Kinase">HSV-TK</A> enzyme with purine nucleoside analog <A class="tue-tooltip" data-toggle="tooltip" data-placement="top" title="" data-original-title="Ganciclovir">GCV</A> as a prodrug. Systemic administration of the prodrug Ganciclovir induces cell death only in the cells that express the HSV-Thymidine Kinase enzyme, sparing the life of the cells that do not express this enzyme. <SPAN class="tue-reference"><SPAN class="tue-refid">aghiEtAlGCVFlu</SPAN>M. Aghi, C.M. Kramm, T.C. Chou, X.O. Breakefield, E.A. Chiocca, Synergistic Anticancer Effects of Ganciclovir/Thymidine Kinase and 5-Fluorocytosine/Cytosine Deaminase Gene Therapies. <I>Journal of the National Cancer Institute</I><B>90</B>, 370-380 (1998)</SPAN> depicts the complete process of cell death induced by the HSV-TK/GCV system.
</P><P>
We propose to use this system as our killing mechanism, considering that it is well characterized and used in applications related to the principle of our device. However at this point of our project the <I>in vitro</I> implementation of this system is not possible and thus we focused on a pharmacokinetics model of the prodrug distribution in the body and the elimination of the CEST protein producing bacteria from the system. The following section describes the main results from the pharmacokinetics model.
</P><H2><SPAN class="mw-headline" id="The_TK.2FGCV_System:_Implementation">The TK/GCV System: Implementation</SPAN></H2><P>We developed a pharmacokinetics model of the prodrug  Ganciclovir distribution and the systemic elimination of the CEST protein production device. The model and results can be found in the <A href="/Team:TU-Eindhoven/PBPK" title="Team:TU-Eindhoven/PBPK"> Drylab section</A> of our wiki. The results from the pharmacokinetics model indicate that when administrating 5mg/L of Ganciclovir intravenously to the patient per day, the drug reaches its highest concentration on the tumor region of approximately .23mg/L in 50 hours since treatment. This concentration gradually decreases over the following hours after administration of the prodrug. The total elimination rate of the Ganciclovir is 1.2748 h<SUP>-1</SUP>. Furthermore, the elimination of bacteria due to the effect of the Ganciclovir is depicted in the following plots ( and ).
</P><DIV class="tue-float tue-float-left span6"><DIV class="tue-caption"><SPAN class="tue-caption-figure"><SPAN class="tue-refid">bacteriaGrowthRate</SPAN></SPAN> <SPAN class="tue-caption-text">Growth Rate of Bacteria under GCV administration</SPAN></DIV></DIV><DIV class="tue-float tue-float-right span6"><DIV class="tue-caption"><SPAN class="tue-caption-figure"><SPAN class="tue-refid">bacteriaDensity</SPAN></SPAN> <SPAN class="tue-caption-text">Bacteria Density in Tumor under GCV administration</SPAN></DIV></DIV><H2><SPAN class="mw-headline" id="The_Alternative_System:_The_5-Fluorocytosine.2F_Cytosine_Deaminase_System">The Alternative System: The 5-Fluorocytosine/ Cytosine Deaminase System</SPAN></H2><DIV class="tue-float tue-float-left span8"><DIV class="tue-caption"><SPAN class="tue-caption-figure"><SPAN class="tue-refid">kmIFigure1</SPAN></SPAN> <SPAN class="tue-caption-text">Cell death induced by the 5-Fluorocytosine/ Cytosine Deaminase system in the CEST protein producing bacteria.</SPAN></DIV></DIV><P>Similar to the HSV-TK/GCV GDEPT system, is the <I>Escherichia coli</I><A class="tue-tooltip" data-toggle="tooltip" data-placement="top" title="" data-original-title="cytosine deaminase">CD</A> enzyme with prodrug 5-fluorocytosine.  Like the prodrug Ganciclovir, systemic administration of the prodrug 5-fluorocytosine induces cell death only in the cells that express the cytosine deaminase enzyme.  Cell death is induced when the CD deaminates the prodrug 5-fluorocytosine, forming 5-fluoro-uracil, which is further metabolized into <A class="tue-tooltip" data-toggle="tooltip" data-placement="top" title="" data-original-title="5-fluoro-28-deoxyuridine-58-monophosphate">FdUMP</A>. FdUMP inhibits the enzyme thymidylate synthetase which converts dUMP into  <A class="tue-tooltip" data-toggle="tooltip" data-placement="top" title="" data-original-title="thymidylate">dTMP</A>. The inhibition of the enzyme causes the inhibition of DNA synthesis, leading to cell death. <SPAN class="tue-refagain" id="tue-refagain-aghiEtAlGCVFlu">aghiEtAlGCVFlu</SPAN> Figure 2 shows a detailed graphic explanation of the complete process. 
</P><P>Given that the chassis of our device is<I> E. coli</I>, the implementation of the CD/5’fluorocytosine system on our device could be an alternative to the HSV-TK/GCV system. We didn’t explore this alternative further but we will consider it when testing the kill switch <I>in vitro</I> in case the HSV-TK/GCV is not successful in inducing cell death in our CEST protein producing bacteria.
</P><H2><SPAN class="mw-headline" id="References">References</SPAN></H2></DIV><DIV class="tue-gototop-sticky"><A href="#top" title="Go to the top of the page">Go to Top   </A></DIV><DIV class="printfooter">
Retrieved from &quot;<A href="http://2013.igem.org/Team:TU-Eindhoven/KillingMechanism">http://2013.igem.org/Team:TU-Eindhoven/KillingMechanism</A>&quot;</DIV></DIV></DIV><DIV id="footer-box" class="noprint"><DIV id="footer"><UL id="f-list"><LI id="t-recentchanges"><A href="/Special:RecentChanges" title="Recent changes">Recent changes</A></LI><LI id="t-whatlinkshere"><A href="/Special:WhatLinksHere/Team:TU-Eindhoven/KillingMechanism" title="List of all wiki pages that link here [j]" accesskey="j">What links here</A></LI><LI id="t-recentchangeslinked"><A href="/Special:RecentChangesLinked/Team:TU-Eindhoven/KillingMechanism" title="Recent changes in pages linked from this page [k]" accesskey="k">Related changes</A></LI><LI id="t-specialpages"><A href="/Special:SpecialPages" title="List of all special pages [q]" accesskey="q">Special pages</A></LI><LI><A href="/Special:Preferences">My preferences</A></LI></UL></DIV><DIV id="footer"><UL id="f-list"><LI id="t-print"><A href="/wiki/index.php?title=Team:TU-Eindhoven/KillingMechanism&amp;printable=yes" title="Printable version of this page [p]" accesskey="p">Printable version</A></LI><LI id="t-permalink"><A href="/wiki/index.php?title=Team:TU-Eindhoven/KillingMechanism&amp;oldid=331072" title="Permanent link to this revision of the page">Permanent link</A></LI><LI id="privacy"><A href="/2013.igem.org:Privacy_policy" title="2013.igem.org:Privacy policy">Privacy policy</A></LI><LI id="disclaimer"><A href="/2013.igem.org:General_disclaimer" title="2013.igem.org:General disclaimer">Disclaimers</A></LI></UL></DIV></DIV></DIV></BODY></HTML>